Skip to content

CHELSEA THERAPEUTICS INTERNATIONAL, LTD.: 10-K filed 2012-03-07

What CHELSEA THERAPEUTICS INTERNATIONAL, LTD. reported in its annual report filed 2012-03-07 (fiscal FY 2011): 26 published measures, 91 facts as tagged in accession 0001193125-12-101178.

This filing

Form
10-K (annual report)
Filed
2012-03-07
Fiscal period
fiscal FY 2011
Accession
0001193125-12-101178 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CHELSEA THERAPEUTICS INTERNATIONAL, LTD. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-12-3146,902,705USD
At 2010-12-3148,373,908USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2011-12-3113,237,895USD
At 2010-12-3113,186,144USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-12-3133,664,810USD
At 2010-12-3135,187,764USD
At 2009-12-3112,851,906USD
At 2008-12-3124,547,897USD
At 2007-12-3157,966,579USD
At 2006-12-3114,136,556USD
At 2005-12-312,384,404USD
At 2004-12-3110,541,214USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-12-3141,106,301USD
At 2010-12-3147,593,055USD
At 2009-12-3122,294,649USD
At 2008-12-3121,532,553USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-50,452,165USD365
2002-04-03 to 2011-12-31-183,325,501USD3560
2010-01-01 to 2010-12-31-37,330,069USD365
2009-01-01 to 2009-12-31-25,771,914USD365
2008-01-01 to 2008-12-31-35,086,151USD366
2007-01-01 to 2007-12-31-15,081,545USD365
2006-01-01 to 2006-12-31-8,671,376USD365
2005-01-01 to 2005-12-31-7,915,722USD365
2004-01-01 to 2004-12-31-3,016,559USD366

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-48,039,584USD365
2002-04-03 to 2011-12-31-160,601,498USD3560
2010-01-01 to 2010-12-31-32,251,773USD365
2009-01-01 to 2009-12-31-30,390,169USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2011-01-01 to 2011-12-31227,468USD365
2002-04-03 to 2011-12-31714,473USD3560
2010-01-01 to 2010-12-31151,836USD365
2009-01-01 to 2009-12-3114,037USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-01-01 to 2011-12-3146,280,470USD365
2002-04-03 to 2011-12-31206,956,862USD3560
2010-01-01 to 2010-12-3146,213,160USD365
2009-01-01 to 2009-12-3116,591,302USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-4,727,640USD365
2002-04-03 to 2011-12-31-5,249,063USD3560
2010-01-01 to 2010-12-3111,337,019USD365
2009-01-01 to 2009-12-3114,560,963USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2011-12-31291,024USD
At 2010-12-31180,021USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-01-01 to 2011-12-312,648,741USD365
2002-04-03 to 2011-12-318,990,656USD3560
2010-01-01 to 2010-12-311,986,755USD365
2009-01-01 to 2009-12-311,673,165USD365
2008-01-01 to 2008-12-311,405,752USD366
2007-01-01 to 2007-12-31828,626USD365
2006-01-01 to 2006-12-31283,983USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-50,613,993USD365
2002-04-03 to 2011-12-31-188,008,672USD3560
2010-01-01 to 2010-12-31-37,502,563USD365
2009-01-01 to 2009-12-31-30,350,232USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-12-3146,573,414USD
At 2010-12-3148,155,792USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2002-04-03 to 2011-12-31258,348USD3560
2010-01-01 to 2010-12-3170,389USD365
2009-01-01 to 2009-12-31149,019USD365

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2011-12-314,866,356USD
At 2010-12-312,288,241USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-01-01 to 2011-12-3150,613,993USD365
2002-04-03 to 2011-12-31188,008,672USD3560
2010-01-01 to 2010-12-3137,502,563USD365
2009-01-01 to 2009-12-3130,350,232USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-01-01 to 2011-12-3137,270,138USD365
2002-04-03 to 2011-12-31145,760,423USD3560
2010-01-01 to 2010-12-3130,871,125USD365
2009-01-01 to 2009-12-3123,985,118USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-12-3162,034,146shares
At 2010-12-3149,790,975shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2011-12-31216,984,108USD
At 2010-12-31168,056,121USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2011-12-3138,267USD
At 2010-12-3138,095USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2011-12-315,245,339USD
At 2010-12-318,950,469USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2011-12-31793,521USD
At 2010-12-31246,374USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-01-01 to 2011-12-315,276,146USD365
2002-04-03 to 2011-12-3125,223,673USD3560
2010-01-01 to 2010-12-314,154,944USD365
2009-01-01 to 2009-12-314,075,663USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2011-01-01 to 2011-12-31116,465USD365
2002-04-03 to 2011-12-31421,979USD3560
2010-01-01 to 2010-12-3175,610USD365
2009-01-01 to 2009-12-3169,431USD365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2009-01-01 to 2009-12-314,390,487USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2002-04-03 to 2011-12-31224,328USD3560
2010-01-01 to 2010-12-3170,389USD365
2009-01-01 to 2009-12-31149,019USD365

Inspect the source

Entity
CHELSEA THERAPEUTICS INTERNATIONAL, LTD. / CIK 0001333763
Captured
SEC response SHA-256
354bb9243ece9eacb7fe265090cbbf659edca4a013cc87523793af082dfdb51c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001333763.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))